VIA
ANIK icon

Vident Investment Advisory’s Anika Therapeutics ANIK Stock Holding History

Vident Investment Advisory’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,639
Closed -$402K – 399
2015
Q3 		$402K Buy
12,639
+5,090
+67% +$177K 0.06% 622
2015
Q2 		$249K Buy
7,549
+279
+4% +$9.95K 0.03% 717
2015
Q1 		$299K Buy
+7,270
New +$294K 0.06% 636

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Vident Investment Advisory's ANIK Position: Q4 2015 in Review

Vident Investment Advisory sold out of Anika Therapeutics (ANIK) in Q4 2015, closing a stake of 12,639 shares — an estimated $402K sold.

Vident Investment Advisory first reported a position in ANIK in Q1 2015 and held it in 3 quarters. The position peaked at $402K in Q3 2015. 152 funds tracked by Wall St. Rank hold ANIK as of Q4 2015.

  • Vident Investment Advisory reported no remaining Anika Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Vident Investment Advisory sold 12,639 Anika Therapeutics shares in Q4 2015, an estimated $402K.
  • Vident Investment Advisory first reported a position in Anika Therapeutics in Q1 2015 and held it in 3 quarters.
  • Vident Investment Advisory's Anika Therapeutics position peaked at $402K in Q3 2015.
  • 152 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2015.

Based on Vident Investment Advisory's 13F filing for Q4 2015, filed 17 Feb 2016.